Immunotherapy in atopic dermatitis

• Published in: Expert opinion on investigational drugs Vol. 10; no. 1; p. 49
• Main Author: Mastrandrea, F
• Format: Journal Article
• Language: English
• Published: England 01.01.2001
• Subjects: Allergens - immunology; Dermatitis, Atopic - etiology; Dermatitis, Atopic - therapy; Humans; Immunosuppressive Agents - therapeutic use; Immunotherapy; Interferon-gamma - therapeutic use
• ISSN: 1354-3784
• DOI: 10.1517/13543784.10.1.49

Atopic dermatitis (AD) is a common inflammatory disease involving the skin and often other organs and systems, mainly respiratory. A definitive general consensus on the AD pathogenesis has not yet been established, however several lines of evidence suggest that T-cells play a crucial role in priming AD early-stage lesions. Main topics involved in the disease pathogenesis have been reviewed, which considered the concept of local and systemic haemopoietic events as important contributors to allergic inflammation, a concept now achieving great acceptance. The recently recognised atopic nature of the skin inflammation in AD has raised increasing interest for treatment with allergen-specific immunotherapy. However, we only found eight studies using specific immunotherapy (SIT) in AD, two double-blind, placebo-controlled (DBPC) and six observational. One controlled and five observational reported favourable outcomes. The one unique study providing negative results was flawed by the ineffective oral route of extract administration. Despite being encouraging, the reported results do not allow definitive conclusions based on meta-analytic techniques because the amount and quality of information in the literature is not sufficient. The highly promising sub-lingual immunotherapy (SLIT) is discussed with its potential capability of controlling not only the skin lesion severity but also its capability of preventing the development of atopic dermatitis into asthma.